Context: Vitamin D may be a modifiable risk factor for inflammatory bowel disease (IBD).
T he two major forms of inflammatory bowel disease (IBD), Crohn disease (CD) and ulcerative colitis (UC), are chronic inflammatory disorders of the gastrointestinal tract with an increasing incidence worldwide (1, 2) . Although the etiology and pathogenesis of IBD remain largely unknown, both environmental and genetic factors have been implicated in disease development (3) (4) (5) (6) . As an important immunomodulator of both the innate and adaptive immune systems (7) , vitamin D has attracted considerable interest as one environmental factor that may be implicated in the development of IBD (8) (9) (10) (11) (12) . In support of this, a north-south gradient in the incidence of CD and UC exists, with higher incidences at higher latitudes. This could be partially due to lower sun exposure, that is, lower endogenous vitamin D production at higher latitudes (10) (11) (12) . Furthermore, up to 60% to 70% of individuals with CD and UC have insufficient or deficient vitamin D levels (13) ; this increased prevalence of vitamin D deficiency has been reported for both patients with prolonged disease and those who are newly diagnosed (8, 9) . However, a recent, large, nested casecontrol study on prediagnostic vitamin D levels and risk of IBD did not confirm an association between plasma vitamin D level and IBD (14) .
With regard to vitamin D and the development of IBD, the question of causality remains unanswered. Because traditional observational epidemiology is susceptible to confounding and reverse causation, we adopted a different approach: the Mendelian randomization design (15) . The Mendelian randomization design utilizes that genes are randomly distributed at conception, leading to an equal distribution of confounding factors among different genotypes, and that germline DNA is unaffected by disease occurring later in life (15) . Three key assumptions must be fulfilled in Mendelian randomization: First, the genotypes must be associated with the exposure of interest; second, the genotypes must be randomly distributed and thus independent of any measured and unmeasured confounders; and third, the genotypes must be associated with the outcome only through their association with the exposure (15) . Consequently, if all assumptions are fulfilled and higher vitamin D levels are causally associated with lower risk of IBD, genetic variants associated with higher vitamin D levels should also be associated with lower risk of IBD to the extent predicted by their influence on plasma vitamin D levels. For this purpose, we used four single nucleotide polymorphisms (SNPs) in DHCR7 and CYP2R1 genes involved in vitamin D synthesis and associated with higher plasma 25-hydroxyvitamin D [25(OH)D] levels (16) (17) (18) (19) ; we chose these specific variants because they have the most pronounced effect on plasma 25(OH)D levels, and all are without known pleotropic effects (20) .
In this study of 120,013 individuals from the Danish general population, we tested the hypothesis that high vitamin D level is associated with low risk of CD and UC by using different epidemiological designs. First, we tested whether plasma 25(OH)D levels were associated with CD and UC in a cross-sectional and prospective design. Second, we tested the associations between polymorphisms in DHCR7 and CYP2R1 and plasma 25(OH)D levels. Finally, using the combined 25(OH)Dincreasing allele scores, we tested whether genetically high plasma 25(OH)D levels were causally associated with incident CD and UC as well as performed instrumental variable analysis. The study design is outlined in Supplemental Fig. 1 .
Materials and Methods

Study population
Three study populations were included in the current study: the Copenhagen City Heart Study (CCHS), the Copenhagen General Population Study (CGPS), and a Copenhagen-based cohort of patients with IBD. Written informed consent was obtained from all participants. Ethnicity was determined using the national Danish Civil Registration System: To be classified as being of Danish descent, individuals must be Danish citizens and must have been born in Denmark to parents who were both born in Denmark and had Danish citizenship. Please see the Supplemental Data for further descriptions of the study populations. Follow-up for all three cohorts ended on 14 January 2014.
In total, we included 120,013 individuals in the current study, of whom 35,558 had plasma 25(OH)D levels measured and 115,110 individuals had vitamin D genotypes available (Supplemental Fig. 2 ). In addition, we downloaded genetic risk estimates on 408,455 individuals from the UK Biobank Resource, including 1707 CD cases and 3147 UC cases (21, 22) . , in which case measurements were done on fresh samples. Thus, different storage conditions and delays in measurements existed; however, we do not believe this influenced our measurements for several reasons, as reported previously (18) . First, we found the expected seasonal variation of 25(OH)D levels; second, the median concentrations of 25(OH)D across plasma samples from three different examinations in the CCHS on the same healthy participants with storage times of 10, 20, and 30 years were similar; third, previous studies have shown high stability during storage (23) (24) (25) ; and fourth, the median concentrations observed in our studies are similar to those in comparable populations (26, 27 ). Assay precision was tested daily with interassay coefficients of variance between 10% and 11%.
Plasma 25(OH)D measurements
Genotypes
Genotyping was carried out using TaqMan-based assays (Applied Biosystems, Uppsala, Sweden); because of reruns, genotyping was successful in .99%. We included the vitamin D genotypes with the largest effect on plasma 25(OH)D levels as reported in genome-wide association studies (17, 28) , that is, rs7944926 and rs11234027 in DHCR7 and rs10741657 and rs12794714 in CYP2R1 (18, 19) . These variants are assumed to influence plasma 25(OH)D levels either via synthesis of previtamin D from 7-dehydrocholesterol in the skin (DHCR7) or via conversion of vitamin D to 25(OH)D in the liver (CYP2R1) (16) . We deliberately excluded genetic variants in the vitamin D-binding protein because of unpredictable biological effects on vitamin D activity, and we excluded polymorphisms (e.g., in CYP27B1 and CYP24A1) because of concerns regarding pleiotropic effects (29, 30) . Furthermore, other SNPs were excluded when reported in only one genome-wide association study or when F-statistics and effect sizes were inferior, as described previously (20) . To incorporate yet more results, we also searched for recent genome-wide association study on 25(OH)D levels and included three additional SNPs in the UK Biobank, that is, rs10745742 in AMDHD1, rs8018720 in SEC23A, and rs17216707 in CYP24A1 (31), extracted from a publicly available database of genetic associations in the UK Biobank (geneatlas.roslin.ed.ac.uk/). bCoefficients and P values were extracted for associations with World Health Organization International Classification of Diseases, 8th revision (ICD-8) and 10th revision (ICD-10) K50 and K51.
Other covariates
Covariates were chosen on the basis of their possible influence on plasma 25(OH)D levels or the risk of CD or UC. Please see the Supplemental Data. In the total Copenhagen study population, 653 incident cases of CD and 1265 incident cases of UC were identified and thus were available for genetic analyses. Of these, 58 cases of CD and 113 cases of UC also had 25(OH)D measurements available for observational analyses. In the UK Biobank, we included 1707 CD cases and 3147 UC cases.
End points
This study group previously investigated the validity of the diagnoses used in the Copenhagen studies (33); 63 randomly selected cases of CD and UC were validated according to the criteria of Lennard-Jones (34) , and all cases were confirmed. Furthermore, the diagnoses of CD and UC obtained from the national Danish Patient Registry were previously shown to have high validity (35) .
Statistical analyses
We used STATA/IC v.13.1 (StataCorp, College Station, TX) for all analyses. A x 2 test was used to evaluate HardyWeinberg equilibrium. Differences in baseline characteristics were assessed using the Cuzick test for trend or Fischer's exact test. In all observational analyses, we combined the CCHS and CGPS to maximize statistical power; in genetic analyses, we furthermore included the cohort of patients with IBD. Information on covariates used for adjustments were .98% complete; missing values were imputed using multivariate normal imputation for continuous variables and chained equation for categorical variables; however, without imputation, results were similar.
To adjust for seasonal variation in plasma 25(OH)D levels and change in assays over time, we grouped individual measurements into percentiles and tertiles of plasma 25(OH)D by month and year of sample collection in each study separately and then combined the two studies. Furthermore, all analyses of plasma 25(OH)D were multivariable adjusted for age, body mass index, cumulative smoking, and alcohol consumption on a continuous scale, with sex, smoking status, physical activity during leisure time, income, and comorbidity as categorical covariates.
In cross-sectional analyses investigating the association between plasma 25(OH)D level and IBD, we used restricted cubic spline logistic regression in the CCHS and CGPS combined to calculate ORs with 95% CIs for CD and UC as a function of percentiles of seasonally adjusted plasma 25(OH)D levels. Point estimates for seasonally adjusted plasma 25(OH)D levels in tertiles were calculated with multivariable logistic regression using individuals in the lowest tertile as reference. In all cross-sectional analyses, incident cases were excluded, and only individuals with CD or UC at baseline were compared with individuals without a diagnosis of CD or UC.
For genetic analyses, we constructed a combined unweighted allele score as the sum of the number of plasma 25(OH)Dincreasing alleles (0 to 8), which was further subdivided into five groups to obtain comparable numbers in each group, as done previously (18, 19) . To test whether vitamin D genotypes and the combined allele score were associated with plasma 25(OH)D levels, we used the Cuzick test for trend. To assess the strength of the genetic instruments, we performed linear regression of the individual genotypes and the combined allele scores on plasma 25(OH)D levels, from which F-statistics and R 2 were obtained. An F . 10 indicates sufficient strength to carry out statistically reliable instrumental variable analyses (15) , and R 2 is a measure of variation explained by genotype. In prospective analyses, hazard ratios (HRs) with 95% CIs for CD and UC per 10 nmol/L higher plasma 25(OH)D level were calculated using a multivariable-adjusted Cox regression model with age as time scale and entry at examination date; thus, individuals with a diagnosis of CD or UC before the examination date were excluded. A test for proportionality of hazards over time was performed using graphical methods and residuals; no major violations were observed. Follow-up for each individual began at study entry and ended at death (n = 9341), emigration (n = 136), or end of follow-up, whichever occurred first. Similarly, HRs with 95% CIs for CD and UC per 1 higher combined allele score were calculated using a Cox regression model adjusted only for age and sex, with entry at date of birth or 1977 (start of the Danish Patient Registry; i.e., with delayed entry for those born before 1977, as genotypes are present at birth and therefore precede all events). Analyses using this combined allele score are referred to as analyses of genetically high 25(OH)D and outcomes.
In addition, to take into account the competing risk of death, competing risk analyses were calculated according to Fine and Gray (36) , with subhazard ratios for CD and UC per 10 nmol/L higher plasma 25(OH)D and per 1 higher combined allele score, respectively.
Furthermore, potential causal relationships between plasma 25(OH)D and risk of CD and UC were assessed using the combined allele score, instrumental variable analyses, and the ratio estimator. Genetically determined ORs with 95% CIs were calculated by taking the ratio of the disease-allele score log OR to the exposure-allele score coefficient and then exponentiating to express this as an OR with standard errors derived using the delta method (37). This was calculated for both CD and UC per genetically determined 10 nmol/L higher plasma 25(OH)D level, using the combined plasma 25(OH)D-increasing allele score from 0 to 8 as the genetic instrument and the plasma 25(OH)D levels as the exposure (15, 38) .
Finally, to include newly identified variants associated with change in plasma 25(OH)D levels, we performed additional analyses using data from the Copenhagen studies and the UK Biobank combined and constructed a funnel plot of b-coefficients from a linear regression on a dichotomous outcome (CD and UC as available in UK Biobank (Fig. 1) . In the total study population, 653 individuals were diagnosed with CD, and 1265 individuals were diagnosed with UC from 1977 to 2014. Plasma 25(OH)D levels were associated with most of the included confounders (Table 1; Supplemental  Tables 1 and 2 ). In contrast, the DHCR7 and CYP2R1 genotypes and the combined allele score were not associated with any included confounders, illustrating that the combined allele score can be used as a largely unconfounded instrument to assess the association between lifelong plasma 25(OH)D levels and CD and UC (Table 1; Supplemental Table 3 (Fig. 2) .
Genotypes and plasma 25(OH)D level
DHCR7 rs7944926 and rs11234027 were associated with 10% and 9% higher plasma 25(OH)D levels, respectively, in GG homozygotes compared with AA homozygotes (Fig. 3) . Similarly, CYP2R1 rs10741657 was associated with 8% higher plasma 25(OH)D levels in AA than in GG homozygotes, and rs12794714 with 9% higher plasma 25(OH)D levels in GG than in AA homozygotes (Fig. 3) . For the combined allele score, the difference in plasma 25(OH)D level per 1 higher allele score was 1.4 nmol/L (95% CI: 1.2 to 1.6), corresponding to a 3% increase per allele. The mean plasma 25(OH)D levels ranged from 50.5 nmol/L (95% CI: 49.8 to 51.1 nmol/ L) in the lowest allele score group (0 to 3) to 57.4 nmol/L (95% CI: 56.6 to 58.2 nmol/ L) in the highest allele score group (7, 8) .
Plasma 25(OH)D level, CD, and UC: prospective and genetic analyses
Observationally, 10 nmol/L higher plasma 25(OH)D level was associated with HRs of 1.04 (95% CI: 0.93 to Figure 1 . Kaplan-Meier curves of cumulative incidence of CD and UC by plasma 25(OH)D tertiles. Individuals with a diagnosis before baseline were excluded.
1.16) for CD and 1.13 (95% CI: 1.06 to 1.21) for UC (Fig. 4) . The HRs for a 1-allele increase in the combined allele score were 0.98 (95% CI: 0.94 to 1.03) for CD and 1.01 (95% CI: 0.97 to 1.04) for UC. Genetically determined 10 nmol/L higher plasma 25(OH)D level was associated with HRs of 0.88 (95% CI: 0.64 to 1.21) for CD and 1.04 (95% CI: 0.82 to 1.32) for UC (Fig.  4) . In sensitivity analyses, we performed logistic regression including prevalent cases but excluding incident cases, which gave similar results. Likewise, including total cholesterol and triglycerides in the multivariableadjusted analyses gave similar results (data not shown). Consideration of the competing risk of death gave comparable results, with subhazard ratios per 10 nmol/L higher plasma 25(OH)D levels of 1.05 (95% CI: 0.95 to 1.15) for CD and 1.13 (95% CI: 1.07 to 1.21) for UC; subhazard ratios per 1-allele increase in combined allele score were 0.97 (95% CI: 0.89 to 1.06) for CD and 1.02 (95% CI: 0.95 to 1.09) for UC. (Fig. 5) .
Discussion
In this prospective cohort study of 120,013 individuals from the Danish general population, in contrast to our hypothesis, we found that higher plasma 25(OH)D levels were associated with a higher risk of UC but not CD in observational analyses. However, genetically high plasma 25(OH)D level, that is, the combined 25(OH)Dincreasing allele score in the Copenhagen studies and data from the Copenhagen studies and UK Biobank combined, was not associated with either disease; thus, our results do not support a major role of vitamin D deficiency in the development of CD and UC.
Previous evidence from animal and human studies supported a possible link between vitamin D deficiency and the development of CD and UC. In animal studies of IBD using IL-10 knockout mice, vitamin D deficiency both accelerated the development of IBD symptoms and increased mortality (39) , and observational studies have shown vitamin D deficiency to be more common in patients with CD and UC, both in patients with prolonged disease and in individuals with a new diagnosis (8, 9) . Likewise, an observational study of 504 patients with IBD found that vitamin D deficiency was associated with a lower health-related quality of life and with increased disease activity in patients with CD, but not with ). c In current and former smokers only. f Income was classified differently in the two cohorts: three groups in the CCHS, six groups in the CGPS.
g Defined as ischemic heart disease, stroke, chronic obstructive pulmonary disease, diabetes mellitus, or heart failure before baseline. doi: 10.1210/jc.2018-00250 https://academic.oup.com/jcemincreased risk of hospitalization or surgery (40) . Recently, a study of 965 patients with IBD found that those with low vitamin D status had more contact with the health care system, needed more medical treatment, and experienced more pain than patients with normal vitamin D status (41) . In a double-blind randomized clinical trial with 94 patients with CD in remission, a trend toward a reduction in the risk of relapse was found in the vitamin D-supplementation group (42) . However, former studies demonstrating a positive association between vitamin D deficiency and IBD were based mainly on data using prevalent cases and thus were prone to reverse causation. It remains unclear whether vitamin D deficiency has a role in the development of CD and UC or if it is solely a marker of a more severe phenotype. Few studies have assessed the importance of predisease vitamin D status in the development of IBD in a prospective design. In the Nurses' Health Study, Ananthakrishnan et al. (43) found an association between higher predicted vitamin D levels and a lower risk of incident CD, but not UC. However, that study used predicted plasma 25(OH)D levels derived from questionnaires on lifestyle characteristics known to influence vitamin D status, such as diet, supplemental vitamin D intake, and sun exposure, and not measured plasma vitamin D levels. In our study of 120,013 individuals from the general population, we were able to include 35,558 individuals with plasma 25(OH)D measurements. Thus, we assessed 25(OH)D levels in prevalent cases of CD and UC, as well as the association between plasma 25(OH)D levels and risk of incident CD and UC in a prospective design. Moreover, we included genetically determined vitamin D to assess potential causality between plasma vitamin D level and IBD. Our finding that high levels of plasma 25(OH)D are associated with high risk of UC is in contrast to those of previous studies (13, 43) and also to what we hypothesized. It is possible that our observed association between plasma 25(OH)D level and risk of UC could be due to either residual confounding from unmeasured confounders or reverse causation. However, we found no support for a protective effect of high vitamin D level on IBD, as supported by the recent findings of Opstelten et al. (14) based on another large, prospective cohort study using predisease plasma 25(OH)D measurements from both men and women from the general population. Nevertheless, because we did not study the association between vitamin D status and disease course in prevalent IBD cases, we cannot exclude a potential benefit of vitamin D in these patients.
Major strengths of the current study include the two large cohorts, which are representative of the Danish Multivariable adjustments were for age, sex, body mass index, smoking status, pack-years, physical activity during leisure time, alcohol consumption, income, and comorbidity. Number of individuals and events differs between observational and genetic analyses because cases of CD or UC diagnosed before entry were excluded in observational analyses, whereas both incident and prevalent cases were used in the genetic analyses and because more individuals were genotyped than those who had 25(OH)D measured. For plasma 25(OH)D analyses, we combined the CCHS and the CGPS, and for the genetic analyses, we combined the CCHS (n = 9079), the CGPS (n = 105,602), and a cohort of patients with IBD (n = 429); no individuals overlapped between cohorts. HRs were calculated using Cox proportional hazards regression, and ORs were calculated using instrumental variable analyses.
general population, detailed information on several potential confounders, plasma 25(OH)D measurements in a subset of more than 30,000 individuals, and a prospective study design with a long observation time and no losses to follow-up. Finally, because several other modifiable risk factors, such as physical activity, sunlight exposure, supplemental vitamin D intake, and diet, are associated with vitamin D levels and could have biased our results if also associated with the risk of IBD, we used the Mendelian randomization approach on .120,000 individuals to assess lifelong genetically determined vitamin D status, reducing the risk of reverse causation and residual confounding.
Potential limitations of this study and the Mendelian randomization approach include genetic pleiotropy and linkage disequilibrium (15) ; that is, genetic variants used as instruments have multiple functions or are linked with other genetic loci that may affect outcomes other than via the exposure of interest. Consequently, to avoid possible pleiotropic effects, we deliberately excluded genetic variations in the vitamin D-binding protein (20) , and we included only polymorphisms previously selected by this study group as having the strongest associations with plasma 25(OH)D levels (18) . However, we cannot exclude that other factors in addition to the plasma concentration of 25(OH)D could play a role in the vitamin D-IBD relationship. Also, because the range of mean plasma 25(OH)D levels between the highest and the lowest allele scores was modest, this difference may be too small to be significant, making us prone to type II errors. Furthermore, we included only individuals of Danish descent; therefore, our results may not necessarily apply to all races. However, we are not aware of data suggesting that the present results should not apply to most races in most countries. Because the national Danish Patient Registry does not include patients treated solely by private practice specialists and general practitioners, some CD and UC diagnoses may have been overlooked. Patients initially treated by private practice specialists could have altered their diet or begun vitamin D supplementation before being admitted to a hospital, which could have potentially biased the observational study. This could explain our observed positive correlation between high plasma 25(OH)D level and higher risk of UC; however, the genetic study is not susceptible to such bias. Furthermore, we had 25(OH)D measurements at only a single point in time and could not capture changes in plasma vitamin D exposure over time. In contrast, genetic analyses capture lifelong, altered vitamin D status largely independent of modifiable risk factors and, because genotypes are present at birth, enabled us to include prevalent cases as well.
Nevertheless, because both CD and UC are rare diseases, our study is limited by the lack of power to completely exclude a causal effect of vitamin D on risk of IBD. To illustrate, we would need 33,599,749 individuals to exclude an estimated causal OR per a 1 SD change in 25(OH)D level of 1.07 at a two-sided P value ,0.05, a power of 80%, and 0.6% CD cases. For UC, we would need 1,106,770 individuals with 1% cases to detect an estimated causal OR per a 1 SD change in 25(OH)D level of 1.30 for UC (44) . The corresponding power of the current study including 115,000 individuals with 0.6% CD cases and 1% UC cases is 5% for CD and 15% for UC; thus, even larger studies are needed to confirm our findings.
In conclusion, higher 25(OH)D levels were associated with a higher risk of UC but not of CD in observational studies. However, genetically high plasma 25(OH)D level was not associated with CD or UC. Thus, our findings do not support a major role for vitamin D deficiency in the development of CD or UC.
